Compare NREF & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | CCCC |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.6M | 240.3M |
| IPO Year | 2020 | 2020 |
| Metric | NREF | CCCC |
|---|---|---|
| Price | $14.42 | $2.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $14.75 | $7.25 |
| AVG Volume (30 Days) | 64.6K | ★ 2.0M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 14.07% | N/A |
| EPS Growth | ★ 132.43 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $151,560,000.00 | $30,108,000.00 |
| Revenue This Year | $23.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.62 | ★ N/A |
| Revenue Growth | ★ 107.15 | N/A |
| 52 Week Low | $12.14 | $1.09 |
| 52 Week High | $16.80 | $4.26 |
| Indicator | NREF | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 34.04 |
| Support Level | $14.25 | $2.00 |
| Resistance Level | $14.64 | $2.69 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 0.93 | 3.55 |
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.